The graph illustrates the number of flu-related deaths in the United States for each flu season from 2010-2011 to 2023-2024*. The x-axis represents the flu seasons, labeled from '10-11 to '23*-24*, while the y-axis shows the annual number of flu deaths. Throughout this period, flu deaths vary significantly, ranging from a low of 4,900 in the 2021-2022* season to a high of 51,000 in both the 2014-2015 and 2017-2018 seasons. Other notable figures include 36,000 deaths in 2010-2011, 42,000 in 2012-2013, and a recent increase to 28,000 in the 2023*-2024* season. The data exhibits considerable fluctuations with no consistent upward or downward trend, highlighting the variability in flu mortality rates over the years. This information is presented in a line graph format, effectively showcasing the yearly changes and peaks in flu-related deaths across the United States.

*Data for the 2021-2022 and 2022-2023 seasons are estimated.

The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2023-2024 flu season, around 28,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses. Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 32 per 100,000 population during the 2023-2024 flu season. In comparison, the mortality rate for those aged 50 to 64 years was 9.1 per 100,000 population. Flu vaccinations The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2022-2023 flu season, only 35 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2022-2023 flu season, vaccinations prevented over 929 thousand influenza cases among children aged 6 months to 4 years.

WHO: Influenza A (H1N1): Number of Deaths: Australia data was reported at 10.000 Person in 06 Jul 2009. This records an increase from the previous number of 9.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Australia data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 10.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 21 Jun 2009. WHO: Influenza A (H1N1): Number of Deaths: Australia data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

Influenza, also called the flu, is one of the most infectious diseases worldwide. Its symptoms range from mild to severe, and include sore throat, cough, runny nose, fever, headache, and muscle pain, but can also cause severe illness and death among high-risk populations such as the elderly and children. During the 2023-2024 flu season, there were 40 million cases of influenza in the United States. Influenza deaths Although influenza does not require medical attention for most people, it can be deadly, and causes thousands of deaths every year. The impact of influenza varies from year to year. The number of influenza deaths during the 2023-2024 flu season was 27,965. The vast majority of deaths attributed to influenza during the 2023-2024 flu season occurred among those aged 65 years and older. Vaccination An annual influenza vaccination remains the most effective way of preventing influenza. During the 2022-2023 flu season, influenza vaccinations prevented an estimated 2,479 deaths among U.S. adults aged 65 years and older. Although, flu vaccinations are accessible and cheap, a large share of the United States population still fails to get vaccinated every year. In 2022-2023, only 35 percent of those aged 18 to 49 years received a flu vaccination, much lower compared to children and the elderly.

This datasets displays the summary of the Geographic Spread of Influenza throughout the United States for the week ending on 5.10.2008. Each state is given a flu Status that is dependent on the spread of influenza throughout the state for the particular week. There are five levels of status that a state can obtain. They are: * No Activity: No laboratory-confirmed cases of influenza and no reported increase in the number of cases of ILI. * Sporadic: Small numbers of laboratory-confirmed influenza cases or a single laboratory-confirmed influenza outbreak has been reported, but there is no increase in cases of ILI. * Local: Outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in a single region of the state. * Regional: Outbreaks of influenza or increases in ILI and recent laboratory confirmed influenza in at least 2 but less than half the regions of the state. * Widespread: Outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in at least half the regions of the state. The information comes from the Centers for Disease Control and Prevention (CDC) To see more information about how this status is determined see http://www.cdc.gov/flu/weekly/fluactivity.htm for a full explanation of their system.

WHO: Influenza A (H1N1): Number of Deaths: Kuwait data was reported at 0.000 Person in 06 Jul 2009. This stayed constant from the previous number of 0.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Kuwait data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 0.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 06 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Kuwait data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Percent of tests positive for a pathogen is one of the surveillance metrics used to monitor respiratory pathogen transmission over time. The percent of tests positive is calculated by dividing the number of positive tests by the total number of tests administered, then multiplying by 100 [(# of positive tests/total tests) x 100]. These data include percent of tests positive values for the detection of severe acute respiratory virus coronavirus type 2 (SARS-CoV-2), the virus that causes COVID-19 and Respiratory syncytial virus (RSV) reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS), a sentinel network of laboratories located through the US, includes clinical, public health and commercial laboratories; additional information available at: https://www.cdc.gov/surveillance/nrevss/index.html. Influenza results include clinical laboratory test results from NREVSS and U.S. World Health Organization collaborating laboratories; more details about influenza virologic surveillance are available here: https://www.cdc.gov/flu/weekly/overview.html. Data represent calculations based on laboratory tests performed, not individual people tested. RSV and COVID-19 are limited to nucleic acid amplification tests (NAATs), also listed as polymerase chain reaction tests (PCR). Participating laboratories report weekly to CDC the total number of RSV tests performed that week and the number of those tests that were positive. The RSV trend graphs display the national average of the weekly % test positivity for the current, previous, and following weeks in accordance with the recommendations for assessing RSV trends by percent (https://academic.oup.com/jid/article/216/3/345/3860464). All data are provisional and subject to change.

Snapshot img

Influenza Vaccine Market Size 2024-2028

The influenza vaccine market size is forecast to increase by USD 3.76 billion at a CAGR of 8.09% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence and incidence of severe influenza cases, particularly among children. The Global Influenza Program's emphasis on vaccination as a preventative measure is driving market expansion. Combination vaccines, which offer protection against multiple strains of the virus, are gaining popularity due to their convenience and effectiveness. Furthermore, the development of mRNA vaccines, which utilize advanced technology to produce a more potent immune response, is a promising trend in the market. The market for Influenza vaccines encompasses various types, including inactivated vaccines, live attenuated vaccines, quadrivalent vaccines, mono vaccine, trivalent vaccines, pnemucoccol vaccine, pediatric vaccines, and adult vaccines. Despite these advancements, challenges persist, including the difficulty in diagnosing influenza due to its non-specific symptoms and the need for annual revaccination to maintain immunity. Overall, the market is poised for continued growth as the demand for effective vaccines to prevent the spread of influenza remains high.

Market Analysis

Request Free Sample

The market is a significant sector within the global healthcare industry, with a continuous demand due to the seasonal nature of the influenza virus and the ongoing threat of potential pandemics. This market caters to various demographics, including children and adults, through various vaccine types and administration methods. Seasonal influenza vaccines are the primary focus of the market, with two main types: inactivated vaccines and live attenuated vaccines. Inactivated vaccines, also known as flu shots, use killed viruses to stimulate an immune response, while live attenuated vaccines, or nasal sprays, use weakened live viruses.

Furthermore, both types offer protection against the three or four strains of the virus predicted to cause the most significant impact during a season. Quadrivalent vaccines, a more recent addition to the market, protect against an additional B strain, broadening the scope of coverage and potentially reducing the risk of infection. Trivalent vaccines, which protect against three strains, continue to be available and are often used in mass vaccination programs. The pediatric segment of the market is of significant importance due to the vulnerability of children to severe influenza cases. The global influenza program, a collaborative effort between the World Health Organization (WHO) and various national health organizations, plays a crucial role in ensuring the availability of vaccines for children and other at-risk populations.

In addition, combination vaccines, which offer protection against influenza and other diseases, are gaining popularity in the market due to their convenience and potential for reducing the number of vaccinations required. MRNA vaccines, a newer technology, have shown promising results in clinical trials and may become a significant player in the market in the coming years. The market is influenced by several factors, including the severity of seasonal epidemics, the availability and affordability of vaccines, and the public's perception of vaccine efficacy and safety. Hospital and retail pharmacies serve as essential distribution channels for these vaccines, ensuring they reach the end consumer in a timely and convenient manner.

Furthermore, swine flu vaccines, while not a regular component of the seasonal the market, are produced and distributed in response to outbreaks or pandemics. The production and distribution of these vaccines require a rapid response and significant resources, highlighting the importance of a strong global influenza program and the flexibility of vaccine manufacturers. In conclusion, the market is a dynamic and evolving sector within the healthcare industry. With ongoing research and development, the market continues to offer new solutions to protect against the influenza virus, ensuring public health and safety.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Hospitals and pharmacies
  Government and institutional
  Others


Type

  Live attenuated influenza vaccines
  Recombinant influenza vaccines


Geography

  North America

    Canada
    US


  Europe

    UK


  Asia

    China
    India


  Rest of World (ROW)

By Distribution Channel Insights

The hospitals and pharmacies segment is estimated to witness significant growth during the forecast period.The market in the US is categorized by distribution ch

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Influenza viruses pose a serious threat to human health, infecting hundreds of millions of people worldwide each year, resulting in a significant increase in global morbidity and mortality. Influenza activity has declined at the onset of the COVID-19 pandemic, but the genetic diversity of B/Victoria lineage viruses has increased significantly during this period. Therefore, the prevention and treatment of the influenza B Victoria strain virus should continue to attract research attention. In this study, we found that Atractyloside A (AA), one of the effective components in Atractylodes lancea (Thunb.) DC shows potential antiviral properties. This study shows that AA not only possesses anti-influenza B virus infection effects in vivo and in vitro but also can regulate macrophage polarization to the M2 type, which can effectively attenuate the damage caused by influenza B virus infection. Therefore, Atractyloside A may be an effective natural drug against B/Victoria influenza infection.

Hong Kong SAR (China) Hospital Admission Rates: per 10000 People Aged 65 years and Above data was reported at 0.064 Ratio in 03 May 2025. This records a decrease from the previous number of 0.122 Ratio for 26 Apr 2025. Hong Kong SAR (China) Hospital Admission Rates: per 10000 People Aged 65 years and Above data is updated daily, averaging 0.197 Ratio from Jan 2012 (Median) to 03 May 2025, with 696 observations. The data reached an all-time high of 6.395 Ratio in 15 Jul 2017 and a record low of 0.000 Ratio in 17 Dec 2022. Hong Kong SAR (China) Hospital Admission Rates: per 10000 People Aged 65 years and Above data remains active status in CEIC and is reported by Centre for Health Protection. The data is categorized under High Frequency Database’s Disease Outbreaks – Table HK.D001: Centre for Health Protection: Influenza.

As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.

Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.

Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.

The child mortality rate in the United States, for children under the age of five, was 462.9 deaths per thousand births in 1800. This means that for every thousand babies born in 1800, over 46 percent did not make it to their fifth birthday. Over the course of the next 220 years, this number has dropped drastically, and the rate has dropped to its lowest point ever in 2020 where it is just seven deaths per thousand births. Although the child mortality rate has decreased greatly over this 220 year period, there were two occasions where it increased; in the 1870s, as a result of the fourth cholera pandemic, smallpox outbreaks, and yellow fever, and in the late 1910s, due to the Spanish Flu pandemic.